Cargando…

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia

Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia. The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve the effectiveness of cytarabine against acute myeloid leukemia, a high-do...

Descripción completa

Detalles Bibliográficos
Autor principal:	Momparler, Richard L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750587/ https://www.ncbi.nlm.nih.gov/pubmed/23919448 http://dx.doi.org/10.1186/2162-3619-2-20

Ejemplares similares

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Corneal Epithelial Microcysts due to High-Dose Cytarabine Administration in a Pediatric Acute Myeloid Leukemia Patient
por: Karapınar, Tuba Hilkay, et al.
Publicado: (2012)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13
por: Prajapati, Subhash C, et al.
Publicado: (2022)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine
por: Hwang, Yu-Yan, et al.
Publicado: (2012)

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
por: Momparler, Richard L, et al.
Publicado: (2014)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia
por: Fordham, S E, et al.
Publicado: (2015)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2019)

Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate
por: Arahata, Masahisa, et al.
Publicado: (2015)

A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Crobu, Valeria, et al.
Publicado: (2019)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
por: Kara, Asude, et al.
Publicado: (2017)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Therapy-related acute myeloid leukemia in a patient with B-cell acute lymphoblastic leukemia
por: Gajendra, Smeeta, et al.
Publicado: (2021)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients
por: Capria, Saveria, et al.
Publicado: (2012)

The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C)
por: Tsuda, Masataka, et al.
Publicado: (2017)

The antimicrobial peptide PFR induces necroptosis mediated by ER stress and elevated cytoplasmic calcium and mitochondrial ROS levels: cooperation with Ara-C to act against acute myeloid leukemia
por: Lv, Yudie, et al.
Publicado: (2019)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Therapy-related Acute Myeloid Leukemia Following Treatment for Burkitt's Lymphoma
por: Lee, Seung-Shin
Publicado: (2017)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
por: Sun, Huali, et al.
Publicado: (2023)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Lacrimal gland enlargement in acute myeloid leukemia
por: Koul, Ajaz N., et al.
Publicado: (2013)

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups
por: Riva, L, et al.
Publicado: (2013)

Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis
por: Shimony, Shai, et al.
Publicado: (2022)

Evaluation of acute myeloid leukemia blast percentage on MethylC-Capture Sequencing results
por: Yang, Erna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ifd68ov02c2mjf981aeg6c7b84